North Chesterfield opioid addiction treatment company Indivior PLC is moving toward an additional listing on the Nasdaq Stock Exchange.
Executives with the company, which is already listed on the London Stock Exchange, said Thursday the move is aimed at bringing the company a greater profile. In March, it closed on a $145 million acquisition of Opiant Pharmaceuticals Inc., a company developing a new opioid overdose treatment that’s stronger than Narcan.
Indivior plans to be listed on the Nasdaq under the ticker symbol “INDV.”
“The sole purpose of [listing on the Nasdaq] is to bring additional exposure to both the company as well as the disease space in its largest opportunity market of the United States,” CEO Mark Crossley said on an earnings call. “So, this is about that visibility for the company. And we are excited to be able to go live with that at some point in June.”
Indivior made a name for itself by bringing opioid dependency treatments Suboxone and Sublocade…
Read the full story from the Washington Business Journal.
